Search Results 371-380 of 16776 for GLP-1 agonists
... 1 trial. Phase 4 trials look at long-term safety and effectiveness, after ... - Use of GLP-1, GLP-2, human growth hormone (HGH), dipeptidyl peptidase-4 ...
* Stage 1-3 hormone receptor-positive breast cancer 1. Premenopausal patients being treated with GNRH agonist/antagonist to induce menopause are eligible 2 ...
This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and ...
Mayo Clinic has one of the largest and most experienced practices in the United States, with campuses in Arizona, Florida and Minnesota. Staff skilled in dozens ...
It is also used to treat chronic graft-versus-host disease (cGVHD) in patients who have been treated with 1 or 2 previous treatments that did not work well.
Treatment with GLP-1 agonists and amlyin which cause vagal blockade and may affect central processing of pain. Positive tissue transglutaminase antibodies ...
For oral dosage forms (capsules or tablets):. For idiopathic pulmonary fibrosis: Adults—On Days 1 to 7, 267 milligrams (mg) 3 times a day. On Days 8 ...
The investigators propose to 1) examine the role of SBBO in weight loss occurring in patients with PD and 2) determine the response to its treatment with a ...
Cholinesterase inhibitors. One effect of lost nerve cells is lower levels of a chemical messenger called acetylcholine. This messenger is important for memory, ...
The objectives of this study are to determine whether the InPen® alters the glycemic control and variability in adolescents and emerging adults with type 1 ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!